Authorized purpose: SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K193282 adds AIR Recon DL, a deep-learning reconstruction option intended to improve signal-to-noise ratio and image sharpness and enable shorter acquisitions while preserving those properties, with images and spectra interpreted by a trained physician.
Clinical role
AIR Recon DL operates in the scanner reconstruction pipeline after raw MRI acquisition. A user can enable the option and select a noise-reduction level to improve reconstructed signal-to-noise ratio and sharpness or support a locally validated shorter acquisition.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: The images and/or spectra yield information that may assist in diagnosis when interpreted by a trained physician; depending on the region of interest, contrast agents may be used.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K193282 adds AIR Recon DL, a deep-learning reconstruction option intended to improve signal-to-noise ratio and image sharpness and enable shorter acquisitions while preserving those properties, with images and spectra interpreted by a trained physician.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: MRI acquisitions using compatible RF receive coils and various pulse sequences, imaging techniques, and reconstruction algorithms on the SIGNA Premier system.
Who uses it?Intended users: Trained physicians for interpretation of the images and/or spectra.
What does the software produce?Output: Axial, sagittal, coronal, and oblique images; spectroscopic images, parametric maps and/or spectra; and dynamic images of structures and/or functions of the entire body, with AIR Recon DL improving signal-to-noise ratio and image sharpness.
What is its most important limitation?Key limitation: The images and/or spectra yield information that may assist in diagnosis when interpreted by a trained physician; depending on the region of interest, contrast agents may be used.
Clinical takeaway. Clinical role: SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K193282 adds AIR Recon DL, a deep-learning reconstruction option intended to improve signal-to-noise ratio and image sharpness and enable shorter acquisitions while preserving those properties, with images and spectra interpreted by a trained physician.
Evidence takeaway. Evidence from the reviewed source record: Exact-submission FDA evidence includes manufacturer phantom, digital-object, in vivo, and blinded-reader testing, but public counts and patient outcomes are absent. A later 54-examination SIGNA Premier pediatric knee study found AIR Recon DL could materially change quantitative diffusion metrics at higher spatial resolution, and an independent 7,346-examination outpatient study found the AIR Recon DL group achieved up to a 27% scan-time reduction without a significant room-time reduction. These later studies are product-family evidence and do not establish exact K193282 performance at a new site.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
SIGNA Premier is a 3.0T, 70 cm bore whole-body MRI system for diagnostic imaging across multiple anatomies; K193282 adds AIR Recon DL, a deep-learning reconstruction option intended to improve signal-to-noise ratio and image sharpness and enable shorter acquisitions while preserving those properties, with images and spectra interpreted by a trained physician.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
AIR Recon DL operates in the scanner reconstruction pipeline after raw MRI acquisition. A user can enable the option and select a noise-reduction level to improve reconstructed signal-to-noise ratio and sharpness or support a locally validated shorter acquisition.
MRI acquisitions using compatible RF receive coils and various pulse sequences, imaging techniques, and reconstruction algorithms on the SIGNA Premier system.
Exact FDA submission
Checked 2026-09-19
The exact device description supports these system inputs and capabilities but does not state the dossier's raw-data wording.
Axial, sagittal, coronal, and oblique images; spectroscopic images, parametric maps and/or spectra; and dynamic images of structures and/or functions of the entire body, with AIR Recon DL improving signal-to-noise ratio and image sharpness.
Exact FDA submission
Checked 2026-09-19
The exact indication and device description state these image/spectra outputs and AIR Recon DL image-quality changes; DICOM and the dossier's full output list are not retained.
Professional MRI facilities equipped for a fixed 3.0T whole-body scanner, MR safety controls, patient screening, protocol governance, image interpretation, and ongoing service and quality assurance.
Trained physicians for interpretation of the images and/or spectra.
Exact FDA submission
Checked 2026-09-19
The exact indication identifies the trained physician as the interpreter; it does not establish the dossier's trained-imaging-personnel acquisition role.
The images and/or spectra yield information that may assist in diagnosis when interpreted by a trained physician; depending on the region of interest, contrast agents may be used.
Exact FDA submission
Checked 2026-09-19
This replacement uses the exact indication's interpretation and contrast-agent boundaries rather than unsupported universal-performance and patient-outcome claims.
Exact-submission FDA evidence includes manufacturer phantom, digital-object, in vivo, and blinded-reader testing, but public counts and patient outcomes are absent. A later 54-examination SIGNA Premier pediatric knee study found AIR Recon DL could materially change quantitative diffusion metrics at higher spatial resolution, and an independent 7,346-examination outpatient study found the AIR Recon DL group achieved up to a 27% scan-time reduction without a significant room-time reduction. These later studies are product-family evidence and do not establish exact K193282 performance at a new site.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Exact-submission FDA evidence includes manufacturer phantom, digital-object, in vivo, and blinded-reader testing, but public counts and patient outcomes are absent. A later 54-examination SIGNA Premier pediatric knee study found AIR Recon DL could materially change quantitative diffusion metrics at higher spatial resolution, and an independent 7,346-examination outpatient study found the AIR Recon DL group achieved up to a 27% scan-time reduction without a significant room-time reduction. These later studies are product-family evidence and do not establish exact K193282 performance at a new site.
K193282 AIR Recon DL nonclinical and in vivo performance testing
DesignManufacturer digital-reference-object and phantom testing plus in vivo objective measures and blinded radiologist reader evaluation
PopulationMultiple pulse sequences and anatomies with examples spanning contrast use and pathology; public sample, reader, and site counts not reported
Scopeexact submission
Tested versionSIGNA Premier with AIR Recon DL cleared in K193282
IndependenceSponsor or vendor study
K193282
FDA reports passing nonclinical testing, equivalent or better image legibility, maintained lesion conspicuity, and reader preference, but the public summary does not provide detailed counts, confidence intervals, diagnostic-accuracy endpoints, or patient outcomes.
Impact of Deep Learning Denoising Algorithm on Diffusion Tensor Imaging of the Growth Plate on Different Spatial Resolutions
DesignProspective single-center comparison of AIR Recon DL and non-denoised reconstructions from two left-knee diffusion-tensor imaging acquisitions per participant
Population54 pediatric left-knee examinations acquired at 3T on a GE SIGNA Premier using 2 mm isotropic and 2 x 2 x 3 mm voxel dimensions
Scopeproduct family
Tested versionCommercial AIR Recon DL at 75% noise reduction on SIGNA Premier; software release not reported
Samplen=54
Sites1
IndependenceSponsor or vendor study
PMID 38668397
Three coauthors were GE employees. At 2 mm isotropic resolution, DL reconstruction significantly changed tract count, volume, length, and fractional anisotropy, supporting local validation before quantitative DTI measurements are substituted or trended.
Impact of Deep Learning Image Reconstruction Methods on MRI Throughput
DesignIndependent retrospective pre- and postimplementation comparison across a large multicenter outpatient MRI practice
Population7,346 outpatient brain, spine, shoulder, knee, and pelvis MRI examinations across 10 clinical 1.5T scanners; two scanners used AIR Recon DL, three used a DICOM-based method, and five were nonaugmented
Scopeproduct family
Tested versionCommercial AIR Recon DL on two 1.5T scanners; scanner models and software versions not reported
Samplen=7346
IndependenceIndependent study
PMID 38506618
AIR Recon DL was associated with up to a 27% scan-time reduction for evaluated examination types but no significant room-time reduction. Results were heterogeneous by examination type, and image quality was not directly measured in this operational study.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-1767-2026 includes SIGNA Premier systems that may contain ferrous steel fittings at the rear of the magnet instead of non-ferrous brass fittings, creating a personnel-injury risk if the rear is serviced while the magnet is ramped. FDA lists the recall as open and classified. FDA recall Z-2304-2025 includes SIGNA Premier systems for which planned maintenance may not have checked patient-table caster-lock function, allowing an undocked table to move during patient transfer. FDA lists the recall as open and classified. FDA recall Z-2462-2024 includes SIGNA Premier software RX27.0-RX27.3, RX28.0, RX29.0-RX29.2, MR30.0, and MR30.1. Under specified Low SAR and 2D T2 FLAIR settings, predicted B1+RMS can exceed the prescribed limit and overheat an MR-conditional implant. FDA lists the recall as open and classified. FDA recall Z-1430-2022 affects SIGNA Premier model 5748519 because rare gradient-coil conditions could produce elevated acoustic noise and prolonged exposure could lead to hearing loss. FDA lists the recall as open and classified. FDA recall Z-0590-2022 includes the superconducting magnet used in SIGNA Premier systems because the cryogen ventilation system may not meet venting requirements. FDA lists the recall as open and classified. FDA recall Z-0132-2022 affected SIGNA Premier because some slices could be missing under certain conditions, creating a gap in anatomy in three-dimensional volume images. FDA lists the recall as terminated. FDA recall Z-2052-2021 affected SIGNA Premier because a user intending to select Save RX could inadvertently select Patient Orientation before the initial three-plane localizer, potentially producing incorrectly annotated or flipped images. FDA lists the recall as open and classified.
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Native K193282 and SIGNA Premier match. This is a system hardware and service-access issue, not an AIR Recon DL algorithm defect; verify affected-unit and correction status with GE before rear-magnet service.
Native K193282 and SIGNA Premier match. This is a patient-table maintenance issue, not an AIR Recon DL defect; verify caster locks before transfer and confirm GE inspection or correction status.
Native K193282 and SIGNA Premier match, but the clearance summary does not establish the installed software build. This is an MR sequence and safety-control issue rather than evidence of an AIR Recon DL defect; verify software, optimized-FLAIR configuration, workaround, and correction status.
Native K193282 and exact SIGNA Premier model match. This is a gradient-coil acoustic-safety issue, not an AIR Recon DL algorithm defect; verify affected-unit status, the operator-manual addendum, and use of hearing protection rated at least 33 dB NRR.
Native K193282 and SIGNA Premier component match. This is a facility, magnet, and quench-safety issue, not an AIR Recon DL defect; verify ventilation inspection, evacuation procedures, and correction status.
Native K193282 and SIGNA Premier match. This is a reconstructed-volume completeness issue; the FDA record does not identify AIR Recon DL as the cause. Confirm the correction is installed and preserve image-completeness review controls.
Native K193282 and SIGNA Premier match. This is a user-interface and acquisition-workflow issue, not an AIR Recon DL algorithm-performance finding; verify actual versus prescribed orientation before scanning and confirm correction status.
Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.
Public pricing
No public purchase price for the K193282 SIGNA Premier system or AIR Recon DL option was found. GE lists a separate 3.5-day advanced SIGNA Premier service course at $15,500 tuition only, $16,100 with lodging, or $17,600 with lodging and airfare; these amounts are implementation-cost benchmarks, not scanner, software, maintenance, or clinical-training prices.
These observations are not an exact-product procurement quotation. They are family, vendor, patient-charge, reimbursement, model, or unscoped records and are not comparable across dates, bundles, currencies, or units.
USD 15500
Price observation, scope not stated · one-student, 3.5-day advanced service-training course; tuition-only through tuition, lodging, and airfare options · United States
Observed 2026-09-02
Public GE service-training list prices for biomedical engineers. This is not a scanner price, AIR Recon DL license price, implementation quote, clinical-user course, maintenance agreement, or total-cost estimate.
CMS NCD 220.2 addresses coverage of medically necessary MRI and MRA services performed on FDA-authorized equipment within its labeling; it does not establish a separate payment for SIGNA Premier or AIR Recon DL. Coverage, coding, payment, and prior-authorization analysis remains examination-, payer-, site-, and patient-specific.
No separate named-product payment identified in CMS NCD 220.2
Medicare · United States · Effective 2018-04-10
The NCD provides MRI and MRA coverage context and does not assign payment to AIR Recon DL. Verify the ordered examination, medical necessity, current code set, site of service, payer contract, and local coverage rules.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: MRI acquisitions using compatible RF receive coils and various pulse sequences, imaging techniques, and reconstruction algorithms on the SIGNA Premier system.
Scope: Exact FDA submission. The exact device description supports these system inputs and capabilities but does not state the dossier's raw-data wording.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: AIR Recon DL is embedded in SIGNA Premier reconstruction rather than applied as a separate DICOM post-processing service. The FDA summary describes SIGNA Premier as DICOM conformant, and GE publishes software-specific conformance statements including RX28.0 for the product family.
Scope: Product family. Obtain the conformance statement for the installed build and test worklist, patient demographics, series descriptions, reconstruction metadata, image and presentation-state transfer, routing, failure recovery, and archive behavior end to end.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Fixed on-premises 3.0T whole-body MRI system with a 70 cm bore. K193282 reports no hardware change from the K183231 predicate; AIR Recon DL is enabled within the scanner reconstruction environment.
Scope: Exact FDA submission. A site still needs scanner-room planning, shielding and power review, MR safety zoning, coil and protocol configuration, PACS and RIS integration, acceptance testing, service coverage, and downtime procedures.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Axial, sagittal, coronal, and oblique images; spectroscopic images, parametric maps and/or spectra; and dynamic images of structures and/or functions of the entire body, with AIR Recon DL improving signal-to-noise ratio and image sharpness.
Scope: Exact FDA submission. The exact indication and device description state these image/spectra outputs and AIR Recon DL image-quality changes; DICOM and the dossier's full output list are not retained.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Axial, sagittal, coronal, and oblique images; spectroscopic images, parametric maps and/or spectra; and dynamic images of structures and/or functions of the entire body, with AIR Recon DL improving signal-to-noise ratio and image sharpness.
Scope: Exact FDA submission. The exact indication and device description state these image/spectra outputs and AIR Recon DL image-quality changes; DICOM and the dossier's full output list are not retained.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Fixed on-premises 3.0T whole-body MRI system with a 70 cm bore. K193282 reports no hardware change from the K183231 predicate; AIR Recon DL is enabled within the scanner reconstruction environment.
Exact FDA submission
Checked 2026-09-02
A site still needs scanner-room planning, shielding and power review, MR safety zoning, coil and protocol configuration, PACS and RIS integration, acceptance testing, service coverage, and downtime procedures.
AIR Recon DL is embedded in SIGNA Premier reconstruction rather than applied as a separate DICOM post-processing service. The FDA summary describes SIGNA Premier as DICOM conformant, and GE publishes software-specific conformance statements including RX28.0 for the product family.
Product family
Checked 2026-09-02
Obtain the conformance statement for the installed build and test worklist, patient demographics, series descriptions, reconstruction metadata, image and presentation-state transfer, routing, failure recovery, and archive behavior end to end.
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.
The FDA-cleared workflow requires trained personnel and trained-physician interpretation. GE separately offers a 3.5-day classroom and lab course for biomedical engineers servicing SIGNA Premier systems; this is service training, not evidence of the clinical-user training package supplied with K193282 or of AIR Recon DL protocol competency.
Product family
Checked 2026-09-02
Require role-specific operator, radiologist, physicist, MR safety, service, protocol-approval, artifact-recognition, fallback, and change-control training and document competency before clinical use.
A user can enable AIR Recon DL in the SIGNA Premier reconstruction workflow and select a noise-reduction level to improve signal-to-noise ratio and sharpness or support a shorter locally validated acquisition.
exact submission · checked 2026-09-02
Validate every clinical sequence, anatomy, coil, acceleration factor, reconstruction level, artifact pattern, quantitative output, and fallback with radiologist and physicist approval.
AIR Recon DL processes raw MRI data in the scanner reconstruction pipeline; K193282 reports no hardware change from the K183231 SIGNA Premier predicate.
exact submission · checked 2026-09-02
Confirm installed software and licenses, reconstruction latency, storage and routing effects, rollback, vendor service access, and behavior during partial failure or downtime.
FDA describes the system as DICOM conformant, and GE publishes software-specific SIGNA Premier conformance statements including RX28.0.
product family · checked 2026-09-02
A conformance statement is a planning input, not proof of interoperability. Execute interface, routing, metadata, display, storage-commitment, and recovery tests against each local system.
A 7,346-examination outpatient study found up to a 27% scan-time reduction in the AIR Recon DL group but no significant room-time reduction, so business cases should measure both scanner acquisition time and total room occupancy by examination type.
product family · checked 2026-09-02
Model local benefits using case mix, protocol eligibility, setup and turnover time, staffing, operating hours, demand, payer mix, repeat rates, and whether saved minutes can produce additional completed examinations.
GE continues to market SIGNA Premier as a 3T wide-bore platform and currently presents AIR Recon DL within the family, but later hardware, software, and feature claims may not apply to the K193282 configuration.
product family · checked 2026-09-02
Require a configuration matrix connecting each quoted feature and service commitment to the exact scanner serial number, software build, license, and FDA clearance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
14Source classes checked
12Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 12 PubMed and 6 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 12 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 7 FDA recall candidates were manually reviewed: 7 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 7 postmarket candidate records; 7 have been reviewed (7 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, peer reviewed publication, trial registry, vendor product page, vendor interoperability, vendor pricing observation, reimbursement policy, fda device recall, fda decision summary packet, literature index, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Monitoring: Not publicly available - checked 2026-09-02 - Exact product version
No public exact-version operational-monitoring specification was established. A local program should track protocol and denoising settings, quantitative-measurement drift, image-quality and artifact complaints, repeats and aborted scans, scan and room time separately, DICOM failures, downtime, service actions, software versions, and open recall corrections.
Authorized purpose: Vantage Fortian and Orian 1.5T produce diagnostic MR images of the head and body, including labeled noncontrast angiography, for trained technologists and physician interpretation.
Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.
Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.
Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.